Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

28 articles from the last 90 days matching "diagnosis"

ResearchPUBMEDMar 26

Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

This study looked at how long it takes to diagnose APDS, a very rare immune system disorder that affects only 1-2 people per million. Researchers interviewed patients and doctors in Austria, Germany, and Switzerland and found that people typically wait several years before getting a correct diagnosis because the disease is so uncommon and looks different in different people.

WHY IT MATTERSPatients with APDS face years of diagnostic delay due to the disease's rarity and variable symptoms — understanding these barriers could help doctors recognize APDS faster and reduce the time families spend seeking answers.
💬 Ask your doctorActivated PI3 kinase delta syndrome (APDS)Primary immunodeficiencyRead →
ResearchPUBMEDMar 26

[Shulman syndrome: An atypical presentation of a rare disease].

Shulman syndrome, also called eosinophilic fasciitis, is a rare disease where the tissue layers under the skin become thick and painful. This case describes a man whose condition started after minor injuries and spread throughout his body. Doctors confirmed the diagnosis using a deep skin biopsy and special imaging scans. This article helps doctors recognize unusual presentations of this rare disease.

WHY IT MATTERSThis case report documents an atypical presentation of Shulman syndrome that initially mimicked lymphedema on imaging, helping clinicians recognize and correctly diagnose this rare condition earlier to avoid delayed treatment.
Good to knowEosinophilic fasciitisShulman syndromeScleroderma-like disordersRead →
ResearchPUBMEDMar 26

An agentic system for rare disease diagnosis with traceable reasoning.

Researchers created DeepRare, a computer system that helps doctors diagnose rare diseases faster and more accurately. The system uses artificial intelligence to analyze patient information like symptoms, genetic test results, and medical history to suggest possible diagnoses. This could help patients avoid the long 'diagnostic odyssey' where they see many doctors over years before getting a correct diagnosis.

WHY IT MATTERSPatients with rare diseases spend an average of 5+ years seeking diagnosis with repeated misdiagnoses; DeepRare could dramatically shorten this timeline by providing doctors with AI-powered diagnostic support that integrates genetic and phenotype data.
Good to knowrare diseases (general)Read →
NewsPUBMEDMar 26

[Multilocular mucocutaneous leishmaniasis with perforation of the anterior nasal septum: a rare differential diagnosis].

Leishmaniasis is a rare disease caused by tiny parasites that can affect the skin, mouth, and nose. This article describes an unusual case where a patient developed leishmaniasis that ate through the wall between their nostrils (nasal septum). Doctors from different specialties—ear/nose/throat, infectious diseases, and tropical medicine—had to work together to diagnose and treat this rare form of the disease.

WHY IT MATTERSIf you have unexplained nasal sores, perforations, or mouth ulcers combined with skin lesions—especially after travel to Central/South America or the Mediterranean—leishmaniasis should be considered and requires coordinated care across multiple medical specialties.
💬 Ask your doctorMucocutaneous leishmaniasisLeishmaniasisCutaneous leishmaniasisRead →
ResearchCLINICALTRIALSMar 26

Trial Completed: Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists (NCT07428915)

Researchers completed a study testing whether an AI tool called Legit.Health Plus can help doctors better diagnose rare and complicated skin conditions. The tool was tested with 15 healthcare providers to see if it could reduce the gap between what general doctors and skin specialists diagnose. This matters because conditions like Generalized Pustular Psoriasis and Hidradenitis Suppurativa can be missed or misdiagnosed, delaying proper treatment.

WHY IT MATTERSThis completed trial tested an AI diagnostic tool specifically designed to help primary care doctors accurately identify rare skin conditions like Generalized Pustular Psoriasis and Hidradenitis Suppurativa, which are often missed in non-specialist settings.
Good to knowGeneralized Pustular PsoriasisPustular PsoriasisHidradenitis SuppurativaRead →
ResearchCLINICALTRIALSMar 26

New Clinical Trial: Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) (NCT04358107)

Researchers are studying 1,000 children and adults with adrenocortical carcinoma (ACC), a rare cancer of the adrenal glands. They want to understand why some people survive longer than others and whether certain treatments work better. The average person with ACC lives about 14.5 months after diagnosis, but survival times vary widely.

WHY IT MATTERSThis study is actively collecting data that could help doctors better predict outcomes and choose more effective treatments for ACC patients, though it is not currently recruiting new participants.
💬 Ask your doctorAdrenocortical CarcinomaRead →
Clinical trialCLINICALTRIALSMar 26

Trial Now Recruiting: Diagnosis and Treatment of Patients With Inborn Errors of Metabolism (NCT00369421)

Researchers at the National Institutes of Health are looking for up to 4,000 patients with rare metabolic disorders to study and treat. These are conditions where the body cannot properly break down certain substances because of missing or faulty proteins. Patients will receive exams and treatment, mostly as outpatients, though some may need to stay at the NIH Clinical Center for special tests.

WHY IT MATTERSThis trial offers patients with arterial calcification due to CD73 deficiency direct access to specialized NIH researchers and potential treatment options that may not be available elsewhere.
You can act on thisArterial Calcification Due to Deficiency of CD73Inborn Errors of MetabolismRead →
Clinical trialCLINICALTRIALSMar 26

New Clinical Trial: New Analytic Tools for aHUS and C3G Diagnosis (NCT05985122)

Researchers across 7 European countries are working together to develop better ways to diagnose two rare kidney diseases: atypical hemolytic-uremic syndrome (aHUS) and C3 glomerulonephritis (C3G). This study is enrolling 180 people, including patients with these conditions and healthy volunteers, to test new diagnostic tools that could help doctors identify these diseases more quickly and accurately.

WHY IT MATTERSThis trial is developing improved diagnostic tests for aHUS and C3G, which could help patients get diagnosed faster and start treatment sooner—critical since these complement-mediated kidney diseases can cause permanent kidney damage if left untreated.
Good to knowAtypical Hemolytic-Uremic Syndrome (aHUS)C3 Glomerulonephritis (C3G)Membranoproliferative GlomerulonephritisRead →
← PreviousPage 2 of 2

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases